Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting
09 avr. 2013 15h00 HE
|
Arbutus Biopharma Corporation
TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective Range
Tekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid (Neuroendocrine)...
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results
27 mars 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results
20 mars 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., March 20, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will...
Tekmira Outlines Key 2013 Product Development and Corporate Milestones
12 févr. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference
06 févr. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR
04 févr. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery
31 janv. 2013 16h05 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Acquires Worldwide License to Novel RNAi Technology
29 nov. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results
13 nov. 2012 06h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results
12 nov. 2012 22h35 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...